

TITLE PAGE

Cost -effectiveness of granulocyte colony stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

Authors: Matti S. Aapro^a, MD, Stephen Chaplin^b, BSc, Paul Cornes^c, BM; Sebastian Howe^d, PhD, Hartmut Link^e, MD, PhD, Natalia Koptelova^d, MD, Andrea Mehl^d, MBA, MPHEco, Mario Di Palma^f, MD, Bridgette Kanz Schroader^g, PharmD, MPA, BCOP, Robert Terkola^{h,i}, PhD, MSc, aHPH; .

Affiliations: ^a Genolier Cancer Center, Genolier, Switzerland, ^b Xcenda UK, York, ^c Comparative Outcomes Group, UK, ^d Sandoz International GmbH, Holzkirchen, Germany, ^e Private Practice Hematology Oncology Kaiserslautern, Germany, ^f Gustave Roussy, Paris-Saclay University, Villejuif, France, ^g Xcenda LLC, Carrollton, TX, US, ^h Institute of Science in Healthy Ageing & Healthcare (SHARE, University Medical Center Groningen (UMCG, University of Groningen, The Netherlands), ⁱ Department of Pharmacotherapy and Translational Research, University of Florida -College of Pharmacy, Gainesville, USA

Corresponding author:

Dr Sebastian Howe

Sandoz International GmbH

Industriestr. 18

D-83607 Holzkirchen

Germany

Telephone: +49 8024 4763508

Email address: sebastian.howe@sandoz.com

Online resource 1: Cost inputs

	Breast Cancer	NHL	NSCLC
Austria			
Filgrastim-sndz (price per mcg) ¹	€0.16	€0.16	€0.16
Pegfilgrastim-bmez ¹	€390.86	€390.86	€390.86
Cost of FN event requiring hospitalization (per day) ²	€923.00	€923.00	€923.00
Number of filgrastim doses per chemotherapy cycle ³	5	5	5
Number of pegfilgrastim doses per chemotherapy cycle	1	1	1
Percentage of patients self-administering G-CSF ⁴	34%	34%	34%
Percentage of FN events requiring hospitalisation (Assumption)	100%	100%	100%
Mean length of stay for FN - PP	5.7 ^{5,6}	8.8 ⁷	8.8 ⁷
Mean length of stay for FN - SP	5.4 ^{5,6}	8.8 ⁷	8.8 ⁷
France			
Filgrastim-sndz (cost per mcg) ⁸	€0.20	€0.20	€0.20
Pegfilgrastim-bmez ⁸	€521.73	€521.73	€521.73
Cost of FN event requiring hospitalization (per day) ⁹	€1,317	€1,317	€1,317
Number of filgrastim doses per chemotherapy cycle ³	5	5	5
Number of pegfilgrastim doses per chemotherapy cycle	1	1	1
Percentage of patients self-administering G-CSF ⁴	18%	18%	18%
Percentage of FN events requiring hospitalisation (assumption)	100%	100%	100%
Mean length of stay for FN - PP ¹⁰	5.7	8.0	8.9
Mean length of stay for FN - SP ¹⁰	5.7	8.0	8.9
Germany			
Filgrastim-sndz (cost per mcg) ¹¹	€0.32	€0.32	€0.32
Pegfilgrastim-bmez ¹¹	€998.75	€998.75	€998.75
Cost of FN event requiring hospitalization (per day) ⁷	€355.78	€606.46)	€457.50
Number of filgrastim doses per chemotherapy cycle ³	5	5	5
Number of pegfilgrastim doses per chemotherapy cycle	1	1	1
Percentage of patients self-administering G-CSF ⁴	34%	34%	34%
Percentage of FN events requiring hospitalisation (assumption)	100%	100%	100%
Mean length of stay for FN - PP	5.7 ^{5,6}	8.8 ⁷	8.8 ⁷
Mean length of stay for FN - SP	5.4 ^{5,6}	8.8 ⁷	8.8 ⁷
Abbreviations: FN, febrile neutropenia; G-CSF, Granulocyte colony stimulating factor; mcg, micrograms; PP, primary prophylaxis; SP, secondary prophylaxis. References:			

1. Warenverzeichnis. Österreichische Apotheker-Verlagsgesellschaft m.b.H. 2021, Vienna, Austria. 2021.
2. Austrian Ministry of Social Affairs, Health, Care and Consumer Protection.
<http://www.kaz.bmgf.gv.at/kosten.html>
3. Gascon P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). *Support Care Cancer*. Feb 2016;24(2):911-925. doi:10.1007/s00520-015-2861-z
4. Sandoz. Data on file. 2021;
5. Jacobs VR, Mayer SC, Paessens BJ, et al. Comparison of Actual Hospital Costs versus DRG Revenues for In-Patient Treatment of Febrile Neutropenia during Adjuvant Anthracycline plus/minus Taxane-Based Chemotherapy for Primary Breast Cancer. *Oncology Research and Treatment*. 2011;34(11):614-618. doi:10.1159/000334063
6. Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. *Cochrane Database Syst Rev*. Oct 17 2012;10:CD007913. doi:10.1002/14651858.CD007913.pub2
7. Ihbe-Heffinger A, Paessens BJ, von Schilling C, et al. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. *Onkologie*. 2011;34(5):241-6. doi:10.1159/000327711
8. Ameli l'Assurance Maladie. www.ameli.fr
9. Liste des tarifs applicables à l'AP-HP. "<https://pitiealpetriere.aphp.fr/wp-content/blogs.dir/58/files/2019/03/Affiche-tarifs-mars2019-2.pdf>"
10. Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database]. *Bull Cancer*. Jun 2016;103(6):552-60. Hospitalisations pour neutropenie febrile chimio-induite en France en 2010-2011 : impact clinique et caracteristiques des patients a partir des donnees de la base PMSI. doi:10.1016/j.bulcan.2016.03.012
11. Lauer Taxe. https://www.cgm.com/deu_de/produkte/apotheke/lauer-taxa.html